| Logo | Name | Σ | Employees |
|---|---|---|---|
 |  Advesya Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune 402 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 11 | 10 |
 | Dragonfly Therapeutics, Inc. Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com. immuno-oncology 62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 98 |
 | Skyhawk Therapeutics We Use Small Molecules To Modify RNA Splicing Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com. 71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 66 |
 | Apollomics We are a biopharmaceutical company committed to the discovery and development of mono- and combination cancer therapies. Apollomics is an innovative biotechnology company committed to the discovery and development of oncology combination therapies. With operations in both the U.S. and China, we believe we are well positioned to unlock synergies by leveraging the strengths of partnerships with other biotechnology companies in the East and the West. Since our founding in 2015, under the leadership of our experienced management team with in-depth knowledge and expertise of the evolving cancer treatment landscape, we have built a pipeline of ten (10) drug candidates … 12 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 25 |
 | Zelluna Developing allogeneic TCR-NK therapies for solid tumors Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 30 |
 | BioNTech SE Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress. BioNTech was founded in … 41 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 41 | 5,045 |
 | Sygnature Discovery #EnablingSuccess Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature Discovery has delivered 50 novel pre-clinical and 30 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more. Founded … 75 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 15 | 670 |
 | Sonata Therapeutics Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences … 69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 20 |
 | OxSonics Therapeutics Tackling the toughest cancers. We’re OxSonics, a pioneering clinical-stage therapeutics company committed to developing a ground-breaking platform technology to make anti-cancer drugs smarter, act faster and, above all, work better. Our SonoTran® Platform has been designed to actively enhance the delivery of oncology drugs into solid tumours. SonoTran® is drug agnostic and requires no drug reformulation enabling its use with both existing and novel therapies. We have our own development programs as well as collaborations with Pharmaceutical and biotech companies to work to bring smarter, faster and better therapies to as many patient groups as possible. Drug Delivery, Oncology, Medical … 80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 14 |
 |  Shorla Oncology At Shorla Oncology we develop and commercialize innovative oncology medicines for women’s and pediatric cancers. At Shorla Oncology we develop and commercialize innovative oncology drugs. We focus on indications where existing treatments are limited, in shortage or inadequate for the target population. Our products are the result of Shorla’s world class team encompassing thought leaders, clinicians, scientists and commercial strategists who have extensive experience in the area of drug development and commercialization of niche cancer treatments. Our growing portfolio will bring accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical … 33 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 8 | 50 |
 | AOA Dx Transforming Women’s Health with Breakthrough Cancer Diagnostics and AI AOA Dx is leading a revolutionary breakthrough in early-stage cancer detection for women, leveraging the transformative potential of AI and our proprietary biomarker technology. At the heart of this innovation is our GlycoLocate platform, a multi-omics approach powered by tumor marker gangliosides, lipids and proteins. This platform is setting a new gold standard in the quest for life-saving early cancer diagnostics. We are now advancing AKRIVIS GDTM, a cutting-edge liquid biopsy test designed specifically for the early detection of ovarian cancer. Medical Devices, Diagnostics, Prognostics, Biotechnology, Sales, Commercialization, Regulatory, Licensing, Quality, … 55 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 7 | 54 |
 | LIfT BioSciences World leaders in neutrophil immunotherapies to rejuvenate immune competence in solid tumours and beyond! LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media … 59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 19 |
 | Laevoroc Revolutionizing treatment for leukaemia relapse. Spearheading the development of a novel PNP inhibitor poised to revolutionize treatment for leukaemia patients facing relapse post-stem cell transplantation. Oncology 57 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 4 |
 | Inventiva Pharma A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology. Drug Discovery, Biotech, Oncology, Fibrosis, Lysosomal Storage Disorders, NASH, and SSc 154 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 117 |
 | MacroGenics, Inc. MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies. Our team of 300+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer. Our products and platforms have attracted multiple partnerships with leading pharmaceutical and biotechnology companies around the globe. The Company considers its employees to be its most valuable asset and we are committed to providing opportunities for individuals to learn and grow as a means to further their professional development. MacroGenics' corporate culture promotes an atmosphere of innovation, open communication and teamwork where employees … Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 399 |
 | Aida Oncology Helping cancer patients to get the right drugs Cancer is a disease with millions of variations where even the most effective current treatment protocols will not work for many patients. We at AIDA believe that modern high-performance computing and machine learning combined with cutting-edge gene reading tools can fast forward personalized cancer therapy and improve treatment options for cancer patients. 35 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning | 0 | 10 |
 | iOnctura Developing precision small molecules to combat hard-to-treat tumors. iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer. oncology, drug development, and clinical development 81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 9 | 33 |
 | Anavo Therapeutics BV UNLOCKING THE PHOSPHATASE TARGET CLASS Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications. Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures. drug discovery, phospatase biology, and oncology 39 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 24 |
 | Oniria Therapeutics A shift in cancer treatment methodology makes a world of difference. A shift in cancer treatment methodology makes a world of difference. Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme. Biotechnology, cancer, cell … 57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 17 |
 | Oncimmune - An Alden Scientific Company We understand disease through the lens of the immune system for more effective, safer treatments & better diagnosis. Oncimmune has developed the most advanced and comprehensive analytical platform for the discovery of Antibody / Autoantibody Biomarker Signatures. ImmunoINSIGHTSTM, the best-in-class biomarker discovery engine, provides access to the B cell repertoire and a pivotal class of biomarkers. With one of the world’s largest antigen libraries covering 9000+ human antigens and multi-species variants, we profile antibodies from various biologic samples in very low volume (50 μl). Developed and curated by immunologists and a team of bioinformaticians, we offer high content biological insights … 74 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 40 |
 | Phacilitate Through conferences, community and market insights, we create partnerships that help advance the next pillar of medicine Phacilitate creates an environment where promising innovation can turn into the products that are changing the future of medicine. Recognised as the market leader in providing the life science sector with strategic insight, inspiration and unparalleled business networking, Phacilitate enables professionals to stay abreast of the issues driving life science innovation. #advancedtherapies #biotech #celltherapy #genetherapy Clinical Development, Cell Therapy, Gene Therapy, Oncology, Cancer, Precision Medicine, Biotech, Advanced Therapy, Biotechnology, and Life Sciences 197 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 21 | 19 |
 | TOLREMO therapeutics Stopping non-genetic cancer drug resistance as it emerges TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit. Drug Discovery, Drug Development, Cancer Drug … 20 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 16 |
 | SOLID Therapeutics An early-stage oncology company aiming to treat solid tumors SOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen. We are developing novel cancer therapeutics with dual mode of action targeting both cancer cells and immune cells to treat solid tumors. 105 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 9 |
 |  Galactica Biotech Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies. Our Mission With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people. Drug Discovery, Molecule characterization, Drug repurposing, and Novel compound applications 285 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 0 | 1 |
 | Immunophotonics, Inc. Interventional Immuno-Oncology Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their … 68 similar entities Type: Startup Activities: biotech deeptech legaltech Technologies: Synthetic Biology | 3 | 19 |
 | Nimbus Therapeutics We develop breakthrough medicines for patients through precision small molecule design. Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus' pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, including a WRN program for MSI-H cancers, autoimmune conditions, and metabolic diseases. … 56 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 10 | 110 |
 | Nodus Oncology Developing next generation DDR targeting therapies Nodus oncology is developing first and best-in-class molecules inhibiting novel targets within the DNA damage response and replication stress response. Supported by most recent scientific advances, we are developing the next wave of cancer therapeutics in the DNA damage response (DDR) area. Founded by Cumulus Oncology and in partnership with the Lead discovery Center, Nodus Oncology is developing an innovative portfolio focused on synthetic lethality and collateral vulnerabilities in molecularly defined cancer patient populations Oncology 22 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 4 |
 | Cure51 We want every patient to become a Cancer Survivor. Cure 51 is a TechBio aiming at creating the first ever worldwide database of Cancer Survivors. The company was co-created with leading oncology centres and has already identified more than 1500 survivors in 42 countries across all continents. The company has developed its own data collection and discovery platform as well as a dedicated Central Lab to proceed to a multiomic sequencing of the survivors’ samples. Through this approach, Cure51 will identify robust therapeutic targets, validated by its scientific community, in order to develop novel drugs to cure Cancer. The focus … Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 12 | 49 |
 |  Zionexa Targeted imaging and therapies Zionexa is an international and innovative company developing and commercializing molecular imaging solutions, in-vivo biomarkers for targeted therapies in oncology, to improve patients’ pathway and bring them a better quality of life. Molecular Imaging, Oncology, Targeted therapies, CDx, Radiopharmaceuticals, and Biomarkers 60 similar entities Type: Startup Activities: biotech deeptech | 0 | 6 |
 | Oncofactory 🖇️ Oncofactory, a spin-off of the CNRS, is a science-driven biotech company that provides pharmaceutical and biotech companies with innovative in vivo services to support their non-clinical programs in oncology. Oncofactory joined the ERBC Group in December 2022 to extend its technology to a wider range of customers and provide a one-stop shop for non-clinical studies. 🥚Oncofactory unique technology platform is a New Approach Methodology (NAM) to generate patient tumor replicas in avian embryos (AVI-PDXTM), coupled with state-of-the-art 3D imaging and large-scale molecular analysis for rapid assessment of therapeutic efficacy and in-depth characterization of mechanisms of action to evaluate therapeutic … 5 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 7 |
 | PureTech Health Giving Life to Science PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed … 63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 17 | 90 |
 | PharmEnable Therapeutics Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small molecule drugs PharmEnable is a biopharmaceutical company utilizing AI to discover effective small-molecule medicines for disease targets that are inaccessible to antibodies. With our proprietary AI-enabled drug discovery platform, chemSEEK, we explore new chemical spaces and discover novel small molecules with antibody-like specificity and selectivity. We are developing a pipeline of wholly owned therapeutics with initial focus on oncology and neurology. We also engage in drug discovery partnerships across a range of disease areas where accessing the target poses a significant challenge. PharmEnable is based in Cambridge, … 110 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 17 |
 | DeuterOncology NV Developing deuterated BEST in CLASS MET kinase Inhibitor DeuterOncology NV is a Liege based clinical stage biotechnology company that was founded in September 2020 by Dr Timothy Perera. The company is currently focused on the clinical development of a highly selective brain penetrant, deuterated MET kinase inhibitor DO-2. Drug Development, Deuterated small molecules, and MET kinase inhibitor 66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 4 |
 | NeoPhore Ltd Discovering drugs that create neoantigens NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer. The Company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost … 50 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 22 |
 | Concr Solving data to enable precision therapy for all Concr is a techbio company providing predictive modelling solutions to enhance confidence and foresight about therapeutic efficacy of existing and emerging cancer drugs. By accurately predicting response for individual patients and cohorts, we enable more efficacious and informative trials, thereby improving probability of success of novel cancer therapeutics. Our Farr-Sight® platform, built on decades of astrophysics research, models diverse data interactions to simulate human disease biology, enabling accurate predictions with minimal data. This is especially valuable in early-stage trials and rare cancers. Validated through collaborations with Roche, Step Pharma, The Institute of … 55 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. - Machine Learning A.I. | 9 | 9 |
 | Curve Therapeutics Revolutionary intracellular screening platform enables a new generation of first-in-class drugs. Our mission is to transform the discovery of first-in-class small molecule therapeutics by broadening the landscape of disease targets that can be drugged. Our Microcycle® platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for hit-to-lead programmes. We are deploying our innovative platform to build a pipeline of first-in-class small molecules to address high priority, therapeutically relevant cancer targets. 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 37 |
 | Lantern Pharma Inc. (Nasdaq: LTRN) Leveraging Artificial Intelligence to Rescue and Develop Cancer Therapies Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR … 59 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 1 | 29 |
 | Mablink Bioscience Transforming cancer immunotherapy with next generation ADCs Mablink Bioscience is a French biotechnology company that is actively involved in the fight against cancer by bringing disruptive therapeutic solutions. With its Antibody-Drug Conjugates (ADC) masking technology, Mablink Bioscience aims to dramatically improve the efficiency of ADC therapies and accelerate the development of new treatments. Based in Lyon, where it is developing an unprecedented innovation center, Mablink currently has around 30 employees with diverse backgrounds. biotechnology, drug development, drug discovery, oncology, and R&D 68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 15 | 35 |
 | ElyssaMed SAS ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction. Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 2 |
 | AbTx Antibody for Therapy AbTx is a preclinical stage biotech company developing the next generation of oncology treatments to treat incurable cancers. AbTx platform is developing mAb innovative enzymatic conjugation. Our platform unlock New Frontiers in Medicine to overcome ADC major drawbacks associated targeting solid tumors by generating antibody Fragment Drug Conjugates (FDCs). ADC, Oncology, and drug develoment 69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 5 |
 | INATHERYS Turning Cancer’s Energy Dependency Against Itself: a Shift in Precision Drug Delivery INATHERYS is a clinical-stage biotech advancing precision drug delivery, turning cancer’s energy dependency against itself. Our lead asset, an ADC targeting CD71/TfR1, is designed to address critical needs in treating proliferative cancers. 58 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 13 | 3 |
 | Rosetta Omics Unlocking the road to precision medicine by tumor characterization via high resolution proteomic profiling. Worldwide, there are more than 20 million new cases of cancer each year. First-line therapies are not always the most effective and there is a strong need to move towards personalized medicine by offering the patients the best treatment as quickly as possible. This will help in increasing the chance or cure. Therefore, there is a need to improve the prediction of the response to treatments to be able to save patient’s lives and reduce the cost of expensive inefficient treatments. Our goal is to unlock … Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning | 25 | 10 |
 | Ksilink Patient-based drug discovery We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine. AI image and data analysis, biology, high content screening, high throughput screening, deep learning, assay development, patient stratification, pyschiatric disorders, and cardiac muscle 239 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. Synthetic Biology | 4 | 17 |
 | Pear Bio Patient-centered cancer precision medicine Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery. Our ultimate goal is to optimally allocate approved treatments to cancer patients who will benefit from them, while creating novel therapies that are purpose-designed for patients who don't respond to available treatments. The platform uses microphysiological systems and 3D computer vision to measure cancer progression over time. Pear Bio cultures patient tumor samples with matched blood into 3D immune-microtumors to test potential treatment options and combinations ex vivo. … 26 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 3 | 28 |
 | MEDIBIOFARMA SL To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies 85 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 9 |
 | DIAG2TEC Preclinical CRO in Hematological Cancers Diag2Tec is an expert preclinical CRO devoted to hematological cancers, especially Multiple Myeloma (MM). We focused on in vitro Drug Testing in Human Hematological Cancer derived Cell Lines and Primary Cells from patients with various Hematologic Malignancies (Multiple Myeloma, Diffuse Large B Cells Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Mantle cell Lymphoma, Chronic Lymphoid Leukemia...). With our 2 platforms : Drug Testing Services and ChimioFx, our mission is to provide efficient treatment solutions for patients suffering from Hematological Malignancies with Precision Medicine approaches. We support biotech and phamaceutical companies to focus their drug development on … 26 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 9 |
 | Diatech Pharmacogenetics Leader in the development, production and sales of pharmacogenetics tests for cancer precision medicine. Diatech Pharmacogenetics, the leading Italian Precision Medicine company. Diatech Pharmacogenetics is a provider of molecular diagnostic tools for precision medicine. The company aims at simplifying complex molecular diagnostic procedures into easy end-to-end solutions, from nucleic acids extraction and their molecular analysis, to final reporting. The company has 10 years of experience in the successful implementation of several nucleic acid analysis technologies into regulated diagnostic pipelines; examples include pyrosequencing, mass spectrometry and digital molecular barcoding. Leading cancer centres in Italy and abroad rely on Diatech CE-IVD solutions … 30 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 74 |
 | ASTRA Therapeutics Crafting next generation of small molecule anti-parasitic drugs by harnessing comparative structural data At ASTRA Therapeutics, we are redefining parasite drug development by leveraging the specificity of ParabulinsTM. Our mission is clear: to lead the fight against parasitic diseases with precision-engineered solutions. 505 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 5 |
 | Cellestia Biotech Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, and Inflammatory Disorders 150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 8 |
 | Eisbach Bio GmbH Targeting synthetic lethality in cancer Eisbach Bio is an innovative start-up in biotechnology founded in 2019 as a spin-out of the Biomedical Center Munich. We are developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes. Eisbach will beat cancer at its own game. 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 11 |
 | NEOGAP Therapeutics AB Science for cure. NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden. Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy. Biopharmaceutical company, Immunotherapy, and Immuno-oncology 61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 30 |
 | Orakl Oncology Biology x AI-powered drug development platform to transform precision oncology. Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster. 61 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology | 2 | 22 |
 | TheraPPI Bioscience Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease 76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 5 |
 | Blue Bees Therapeutics Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug 176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 9 |
 | Sirius NeoSight New view for cancer Therapeutic Sirius Neosight is an innovative technological breakdown company which aims to become a key player in the detection of subclashed neo-cancers, relapses and therapeutic monitoring of patients thus offering a new look to doctors on the therapeutic efficiency implemented. Sirius Neosight operates a patented from a patented rupture technology from a consortium of academic laboratory experts in the field. 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 19 | 8 |
 | Tessellate Bio Redefining Synthetic Lethality beyond HRD Tessellate BIO discovers and develops novel precision oncology medicines with the mission to turn cancer patients into cancer survivors. A private preclinical stage biotechnology company, Tessellate BIO is redefining Synthetic Lethality by developing drugs that target unexplored or difficult to drug pathways beyond HRD. Headquartered in the Netherlands and with research labs at the Stevenage Bioscience Catalyst, UK, Tessellate BIO is supported by top-tier life science investors BioGeneration Ventures (BGV) and Forbion. drug discovery, precision oncology, and biotechnology 59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 29 |
 | Kezar Life Sciences Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be … 153 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 59 |
 | Pharm'image #Pharmaco-imaging, #nuclear medicine, #PET/MRI, #Radiochemistry, #Preclinical models Created in 2008 in Dijon, Pharm’image is a regional center of excellence in Pharmaco-imaging. Unique in France, it brings together hospitals, biotechnology, and pharmaceutical companies, to offer state-of-the-art of functional and molecular imaging technologies (MRI, PET, SPECT, CT), ranging from small-animal scale for preclinical experimentation to clinical exploitation Its aim is to deploy cutting-edge medical imaging technologies to evaluate biomarkers that can be used to track treatment efficacy and select the active and most promising drug candidates. imaging, preclinical evaluation, pharmacology, molecular imaging, nuclear medicine, radiochemistry, bioconjugation, translational research, in vivo pharmaco-imaging, First … 57 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 0 | 2 |
 | Regulaxis SAS Regenerative Medicine - Growth Disregulation - Oncology REGULAXIS is a French innovative biotechnology company based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record. REGULAXIS leads its R&D on its own premises, particularly in regard to biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its … 250 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology | 0 | 2 |
 | Syndivia Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy. Drug development, Biotechnology, Pharmaceuticals, Antibody-drug conjugates, DAR1 ADC, and ADC 155 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 6 |
 | Genoscience Pharma Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule 198 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 6 | 3 |
 | XenTech Premium quality preclinical oncology CRO, pioneering the PDX technology for more than 16 years. XenTech is Biotech/Contract Research Organization (CRO) dedicated to translational research in oncology which offers preclinical services to evaluate the anti-cancer potential of drug candidates (PDX, CDX,...) In addition, XenTech develops internal R&D programs to correlate drug response with molecular features of tumors and identify cancer biomarkers and therapeutic targets. patient-derived tumor xenograft models, oncology, biomarkers, efficacy preclinical studies, PDX, CDX, in vivo, and in-vitro assays 14 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 37 |
 | Epitopea Exploiting a new class of tumour specific antigens for cancer therapy A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen. TCR-T cells, Immuno-oncology, Vaccines, Bi-specifics, Splicing, Epigenetics, Oncology, T cell biology, and Antigen presentation 68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 8 | 39 |
 | Mestag Therapeutics New therapies for inflammatory disease and cancer by targeting fibroblast immunology Mestag focuses on fibroblast-immune interactions to develop innovative new treatments for inflammatory disease and cancer. Through our unique understanding of fibroblast immunology, we are advancing a pipeline of first-in-class antibody programs and targets for new treatments. Backed by committed leading global investors, world-class founders and a highly experienced leadership team, Mestag offers an exciting, diverse and balanced place to work, with competitive benefits, generous vacation time and the room to grow and develop your career. biotechnology, fibroblasts, oncology, immuno oncology, inflammatory disease, and datascience 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 55 |
 | Crown Bioscience Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to advancing human health by partnering with biotech and pharmaceutical companies that are at the forefront of drug discovery and development in oncology and immuno-oncology. Providing a range of integrated solutions, including preclinical research services, translational platforms, and clinical trial support. Its offer includes the world's largest commercially available patient-derived xenograft (PDX) collection and more than 600 tumor organoid models utilizing Hubrecht Organoid Technology, covering 22 cancer indications. Crown Bioscience's expertise extends across a diverse portfolio of platforms and services that utilize in vivo, in … 62 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 576 |
 | VitroScan Predicting treatment outcome VitroScan is a Dutch biotech company founded in 2016 and based at the Leiden Bio Science Park. We develop certified predictive ex vivo 3D tumor testing services for reliable treatment response prediction for the clinic and to improve patient stratification for clinical trials. Our proprietary technology provides highly reproducible drug testing in the native tumor microenvironment (TME). VitroScan’s clinical trial program is performed in collaboration with expert clinicians from leading oncology centers. In these trials patient specific ex vivo tumor sensitivity to chemo-, targeted, or immunotherapy is correlated to clinical outcomes. We are dedicated to delivering predictive … 29 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 8 |
 | Talus Bio Unlocking the Regulome for Drug Discovery Talus Bio is making the regulome visible and druggable. We are building the first platform to map, model, and ultimately write the regulome, unlocking thousands of previously undruggable targets, including transcription factors that drive cancer, autoimmunity, and neurodegeneration. Our platform measures the regulome directly in living human cells, generating functional datasets at scale for the first time. These data fuel AI models that learn the logic of genome regulation and predict how to modulate it with precision. 55 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 26 |
 | AUM Biosciences Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules 549 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 18 |
 | Inspirna, Inc. Converting cancer to a manageable, chronic condition Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. Inspirna’s lead drug candidate, ompenaclid (RGX-202), is an orally-administered small molecule that targets the CKB/SLC6A8 pathway, which when activated enables the generation of ATP in response to tumor hypoxia. Ompenaclid is currently being tested in multiple mid-stage clinical trials in patients with advanced or metastatic RAS mutant colorectal cancer. Inspirna’s second clinical stage drug candidate, abequolixron (RGX-104), is an oral small molecule activator of LXR/APOE … 8 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 16 |
 | Dyameo Dyameo is a research company & amp; Development in the field of medical devices which designs aid probes for the diagnosis of in-vivo cancer cells. This medical device, makes it possible to answer the question: "Are these cells cancerous?", And that in a simple, clear and instant manner. This rupture solution proposes to discriminate cancer cells at an early stage, during endoscopic examinations. Medical devices, medtech, and help with in-vivo cancer diantics 65 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 4 | 8 |
 | atbtherapeutics Antibody Targeted Biologics atbtherapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer. 90 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 25 |
 | Predicta Biosciences A precision oncology company integrating multiomics to develop innovative diagnostic and therapeutic products. Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development. 30 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 6 |
 | Cytovation Creating transformative medicines for patients with cancer Cytovation is a clinical stage immuno-oncology biotech developing first-in-class immunotherapies. CY-101, its lead asset, is a synthetic peptide engineered to selectively target tumor cells. CY-101 has a unique dual MoA applicable across solid tumors: (1) direct tumor-specific membrane lysis and in-situ vaccination, combined with (2) immune activation through inhibition of the β-catenin pathway. Building on strong FIH clinical data, Cytovation is advancing CY-101 to POC/pivotal clinical development with a focus on b-catenin-driven cancers. Biotech, Oncology, and Immuno-oncology 33 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 12 |
 | StemTek Therapeutics StemTek Therapeutics is a start-up biotechnolgy company dedicated to accelerating drug discovery in cancer using cutting edge technology, world-class science and a stem cell centric point of view for cancer therapy. Our mission is to help design novel treatments for cancer targeting cancer stem cells. 133 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 1 |
 | AbLeads AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine 576 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 1 |
 | NEBULA Transforming Drug Target Discovery with Physics-Based dataset-free genAI Partnerships At NEBULA, we revolutionize drug discovery by providing a comprehensive, physics-based dataset-free genAI solution for mapping the full range of therapeutic target conformations. Unlike traditional drug development focused on small molecule screening, our innovative approach delves deep into the dynamic nature of macromolecular targets—proteins, mRNA, antigens—unveiling their multitude of physiological conformations. Our dataset-free technology integrates generative genAI with molecular dynamics, rooted in physical principles, to generate an exhaustive profile of potential target structures without relying on pre-existing data. By enhancing the understanding of drug targets, we empower pharmaceutical and biotech companies … 50 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. Generative A.I. | 10 | 5 |
 | Forma Therapeutics Dedicated to transforming the lives of patients with rare hematologic diseases and cancers. Forma Therapeutics (Nasdaq: FMTX) is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. We aim to create futures for patients, their families … 75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 205 |
 | Pyxis Oncology Charting a course to therapeutics for difficult-to-treat cancer. Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies have the potential to address difficult-to-treat cancers and improve patient outcomes. Immuno-oncology and oncology 31 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 3 | 60 |
 | CureMatch, Inc. AI-based Precision Medicine Decision Support for Oncology CureMatch is a leader in AI-based precision medicine, digital decision support solutions that support cancer treatment. Created to empower oncologists with world-class research and sophisticated AI algorithms, the CureMatch Decision Support System assists the doctor with understanding therapeutic options that are personalized to the unique molecular profile of the individual patient’s tumor. digital health, oncology, decision support software, AI, precision medicine, and combination therapy 75 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: A.I. Synthetic Biology | 6 | 26 |
 | Ikena Oncology Patient-directed oncology therapies across pathways relevant in tumor and immune cells Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which … 125 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 22 |
 | Step Pharma Developing selective inhibitors of CTPS1 for patients with cancer and auto-immune diseases Step Pharma is the world leader in the discovery and development of inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases. Step Pharma’s lead program dencatistat (STP938) is a first in class, potent, selective, oral inhibitor of CTPS1 with demonstrated anti-tumor activity. Dencatistat entered clinical development in 2022 in a PhI/II study for the treatment of relapsed and refractory T-cell and B-cell lymphoma. More recently a solid tumour study was started focused on ovarian cancer using the concept of synthetic lethality and … 5 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 14 |
 | Cellomatics Biosciences Ltd Our expertise, Your discovery Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas. Based at Colwick Quays Business Park, Nottingham UK, our experienced scientific team offers bespoke and innovative preclinical in vitro bioassay services to support our client’s drug development programmes. We work with diverse group of global clients including early start-ups, virtual/small to medium sized Biotechnology and Pharmaceutical companies. Multiplex Immunoassay, Target and biomarker validation, In vitro functional assays, Molecular Biology, Receptor binding, Toxicity testing, Immuno-Oncology, Oncology, Immunology, Inflammation, and Respiratory 380 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 19 |
 | Veracyte Biopharma Services Gain actionable insights to confidently advance every step of your oncology drug development programs. Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. We provide novel insights, expertise and capabilities that empower our biopharmaceutical partners to confidently advance every step of their oncology drug development programs. precision medicine, Biopharma, biomarker signatures, and Cancer care 41 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Data Analytics | 24 | 74 |
 | Seekyo Therapeutics Tumor Activated Therapy: targeting Tumor Micro-Environment functional proteins to induce tumor self-destruction The heterogeneity of cancer cells constitutes a strong limitation for the treatment of solid cancers like pancreas and Breast TNBC. Shifting to a new paradigm, Seekyo, a pre-clinical biotech Co. overpowers this challenge by targeting specific functional proteins selectively produced within the Tumor Micro-Environment (TME). Seekyo’s lead compound SKY01 induces a selective tumor self-destruction: • Efficacy and safety validated in small and large animals (e.g. Dogs). • Unprecedented antitumor efficacy vs. Standards of Care • Efficient in several tumors (Pancreas, Triple Negative Breast Cancer, lung, colorectal...) • Low … 46 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 7 |
 | Iksuda Therapeutics Creating class-leading ADCs with enhanced tumor specificity Through our highly experienced ADC Research & Development Team, we are building a pipeline of class-leading ADCs with superior therapeutic index (TI) for difficult-to-treat cancers. Our approach is to develop the best ADC for any given target or tumor sub-type rather than 'technology-driven ADCs'. All our ADCs incorporate tumor-selective release & activation of the most relevant payload according to mechanism, optimizing anti-cancer efficacy and enhancing patient safety. Antibody-Drug Conjugates, PermaLink™, Conjugation Chemistry, Cancer research, ADCs, Drug Development, Therapeutics, Antibodies, Toxins, Cancer Treatment, ADC Stability, Antibody Drug Conjugate, Drug Discovery, Biotechnology, Preclinical, Bioconjugation, Organic … 29 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 43 |
 | ALPIONER Therapeutics Building a pipeline of immuno-therapies to fight against cancer and multiresistant pathogens ALPIONER Therapeutics is a biotech company developing new generation of immunotherapies against cancer and multi-resistant pathogens. Its aT3-plaform is leveraging a bacterial secretion system to inject high quantity of peptides or functional proteins, into the cytosol of the host cell. ALP-102 is a first-in-class vaccine candidate targeting Pa infections while ALP-201-neo is neoantigen-based personnalized cancer vaccine. 67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 18 | 2 |
 | Enterome Delivering the promise of immunotherapy Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. The company is currently developing a pipeline of drug candidates consisting of OncoMimicsTM peptide-based immunotherapies for the treatment of cancer. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin lymphoma, demonstrating a benign … 61 similar entities Tags: FrenchTech2030 Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology | 15 | 42 |
 | Calico Biosystems Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy 542 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 2 |
 | Heidelberg Epignostix GmbH Improving diagnostic accuracy for cancer patients We combine world-leading scientific and medical expertise with cutting-edge technical innovation, to improve diagnostic accuracy and enhance clinical care for cancer patients. The company has developed its expertise since its establishment in 2022, building on decades of combined experience of its founders. We conduct research and development, certification and marketing of software solutions for molecular tumour classification based on DNA methylation profiling and machine learning. Epigenetics, CNS tumours, Brain tumours, Pathology, Precision medicine, and Artificial Intelligence 29 similar entities Type: Startup Activities: deeptech Technologies: A.I. | 3 | 9 |
 | Domain Therapeutics #biopharma #biotech #drugdiscovery #GPCR #Immunooncology #inflammation Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and … 24 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 25 | 80 |
 | Valerio Therapeutics Valerio is a clinical-stage biotechnology company developing novel oncology drugs targeting tumor DNA-binding functions. Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops new drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments. Focusing exclusively on … 25 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 1 | 48 |
 | Relation Discovering the relationships at the heart of biology to cure disease. We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select … 77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 17 | 96 |
 | DISCO Pharmaceuticals GmbH The surfaceome company. DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients. 32 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 28 |
 | Carcinotech Advancing Cancer Treatment Breakthroughs Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3DTM bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization. Cancer research, 3D bioprinting , Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, and early drug discovery 170 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology | 2 | 19 |
 | Infinitopes Preventing deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival. 293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 35 |
 | Hemispherian AS Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Our mission is to develop a new drug to treat Glioblastoma Multiforme. We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients. cancer treatments, GBM treatments, and therapeutics 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 10 |
 | Temple Therapeutics Pioneering a new era in precision medicine for women's health A clinical-stage biotechnology company pioneering a female-focused precision medicine approach using validated biobanks for the discovery, development, and commercialization of novel therapeutics and companion diagnostics in women's health. ovarian cancer, endometrial cancer, fibrosis, endometriosis, post surgical adhesions, surgery, women's health, fitness, health, lifestyle, precision medicine, Artificial Intelligence, Machine Learning, Biobank, gynecology, reproductive medicine, infertility, cervical cancer, pcos, femtech, life sciences, and healthcare 251 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology A.I. | 2 | 7 |
 | ALKemist Bio Next generation cell therapies for ALK-positive cancer patients At ALKemist Bio we are developing TCR-T cells that possess the ability to specifically target ALK antigens found on ALK-positive cancer cells, primarily focusing on non-small cell lung cancer patients. By harnessing the power of the immune system and engineering T cells to precisely recognize and combat these cancerous cells, we aim to pave the way for more effective treatments aiming at improving the standard of care. biotech, immunooncology, oncology, alkpositive, celltherapy, TCR, and ALK 118 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 5 |
 | Brenus Pharma Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣 Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of … 157 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 39 | 21 |
 | BiPER Therapeutics First in class small molecules pushing cancer cells to burn out BiPER Therapeutics is developing a first-in-class pipeline of therapeutics overstressing cells to cure patients. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 13 | 8 |